Results 1 to 10 of about 10,582 (223)

Dihydroartemisinin-piperaquine effectiveness for seasonal malaria chemoprevention in settings with extended seasonal malaria transmission in Tanzania [PDF]

Scientific Reports
Effectiveness of dihydroartemisinin-piperaquine (DP) as seasonal malaria chemoprevention (SMC) was assessed in Nanyumbu and Masasi Districts. Between March and June 2021, children aged 3–59 months were enrolled in a cluster randomized study.
Richard Mwaiswelo, Billy Ngasala, Frank Chaky, Fabrizio Molteni, Ally Mohamed, Samwel Lazaro, Bushukatale Samwel, Bruno P. Mmbando   +7 more
doaj   +6 more sources

Evaluating the effectiveness and cost-effectiveness of integrating mass drug administration for helminth control with seasonal malaria chemoprevention in Ghanaian children: Protocol for a cluster randomised controlled trial. [PDF]

Trop Med Int Health
Objectives To evaluate the effectiveness and cost‐effectiveness of integrating seasonal malaria chemoprevention (SMC) with mass drug administration for helminth control among school‐aged children living in communities where the burden of malaria and ...
Afolabi MO, Adu-Gyasi D, Paintain L, Tawiah T, Ali MS, Greenwood B, Asante KP.   +6 more
europepmc   +4 more sources

Household-level effects of seasonal malaria chemoprevention in the Gambia [PDF]

Communications Medicine, 2023
Background In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention (SMC) to children older than 4 years.
Seyi Soremekun, Bakary Conteh, Abdoullah Nyassi, Harouna M. Soumare, Blessed Etoketim, Mamadou Ousmane Ndiath, John Bradley, Umberto D’Alessandro, Teun Bousema, Annette Erhart, Marta Moreno, Chris Drakeley   +11 more
doaj   +5 more sources

Predictors of caregiver adherence to administration of amodiaquine during delivery of seasonal malaria chemoprevention in Nigeria, Burkina Faso, Chad, and Togo [PDF]

Malaria Journal, 2023
Background Malaria is the leading cause of morbidity and mortality among infants and children under-five in sub-Saharan Africa. In the Sahel, seasonal malaria chemoprevention (SMC) is delivered door-to-door in monthly cycles.
Taiwo Ibinaiye, Olusola Oresanya, Chibuzo Oguoma, Adaeze Aidenagbon, Olabisi Ogunmola, Christian Rassi, Sol Richardson   +6 more
doaj   +5 more sources

Effect of seasonal malaria chemoprevention on incidence of malaria among children under five years in Kotido and Moroto Districts, Uganda, 2021: time series analysis [PDF]

Malaria Journal
Background Seasonal malaria chemoprevention (SMC) refers to monthly administration of full treatment courses of anti-malarial medicine to children
Andrew Kwiringira, Benon Kwesiga, Richard Migisha, Lilian Bulage, Daniel Kadobera, Damian Rutazaana, Julie R. Harris, Alex R. Ario, Julius Ssempiira   +8 more
doaj   +4 more sources

Asymptomatic Plasmodium falciparum infections and determinants of carriage in a seasonal malaria chemoprevention setting in Northern Cameroon and south Senegal (Kedougou) [PDF]

Malaria Journal
Background Among the several strategies recommended for the fight against malaria, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine combination (SPAQ) targets children 3 months to 5 years in Sahel regions of Africa to
Innocent M. Ali, Isaac A. Manga, Akindeh M. Nji, Valery P. Tchuenkam, Peter Thelma Ngwa Neba, Dorothy F. Achu, Jude D. Bigoga, Babacar Faye, Cally Roper, Colin J. Sutherland, Wilfred F. Mbacham   +10 more
doaj   +4 more sources

Impact of seasonal malaria chemoprevention timing on clinical malaria incidence dynamics in the Kedougou region, Senegal. [PDF]

PLOS Glob Public Health
Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine is recommended by the World Health Organization since 2012 for clinical malaria prevention in children in the Sahelian region of Africa.
Kazanga B, Ba EH, Legendre E, Cissoko M, Fleury L, Bérard L, Diop A, Sokhna C, Danfakha F, Sagara I, Ndiaye JL, Gaudart J, Landier J.   +12 more
europepmc   +3 more sources

Understanding and maximising the community impact of seasonal malaria chemoprevention in Burkina Faso (INDIE-SMC): study protocol for a cluster randomised evaluation trial. [PDF]

BMJ Open
Introduction Seasonal malaria chemoprevention (SMC) involves repeated administrations of sulfadoxine-pyrimethamine plus amodiaquine to children below the age of 5 years during the peak transmission season in areas of seasonal malaria transmission.
Moreno M, Barry A, Gmeiner M, Yaro JB, Sermé SS, Byrne I, Ramjith J, Ouedraogo A, Soulama I, Grignard L, Soremekun S, Koele S, Ter Heine R, Ouedraogo AZ, Sawadogo J, Sanogo E, Ouedraogo IN, Hien D, Sirima SB, Bradley J, Bousema T, Drakeley C, Tiono AB.   +22 more
europepmc   +4 more sources

Receipt of seasonal malaria chemoprevention by age-ineligible children and associated factors in nine implementation states in Nigeria [PDF]

Malaria Journal
Background As part of implementation quality standards, community distributors are expected to ensure that only age-eligible children (aged 3–59 months) receive seasonal malaria chemoprevention (SMC) medicines during monthly campaigns.
Taiwo Ibinaiye, Kunle Rotimi, Ayodeji Balogun, Adaeze Aidenagbon, Chibuzo Oguoma, Christian Rassi, Kevin Baker, Olusola Oresanya, Chuks Nnaji   +8 more
doaj   +3 more sources

<i>Plasmodium falciparum</i> <i>dhps</i> and <i>dhfr</i> markers of resistance to sulfadoxine-pyrimethamine five years (2016-2020) after the implementation of seasonal malaria chemoprevention in Cameroon. [PDF]

Wellcome Open Res
Background Antimalarial drug resistance is a major challenge in the fight against malaria. Cameroon implemented seasonal malaria chemoprevention (SMC) with sulfadoxine–pyrimethamine and amodiaquine (SPAQ) to over 1.5 million children aged 3–59 months ...
Tchuenkam PVK, Ngum LN, Ali IM, Chedjou JPK, Nji AM, Netongo PM, Ngwafor R, Niba PTN, Tah CF, Nana WD, Ekoyol G, Bigoga JD, Ashu DF, Tume CB, Mbacham WF.   +14 more
europepmc   +3 more sources